Industry ties may expand indications

Share this article:

A study of government drug review advisory panels suggests that those with members who have financial ties to the drug industry recommended expansion of labeled disease indications for the drugs examined.

Published in the online journal PLOS Medicine, the study by six Australian physicians sought to identify guidelines in which disease definitions were changed, and the extent of panel members' industry ties.

They looked at publications between 2000 and 2013 from guideline panels making decisions about definitions or diagnostic criteria for common conditions in the US. Of 16 publications on 14 conditions, 10 proposed changes widening and one narrowing definitions. Among panels with disclosure, the average proportion of members with ties was 75%.

The authors found that diagnostic thresholds are being lowered by panels dominated by those with financial ties to multiple companies that may benefit from those decisions, raising questions about current processes of disease definition.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Agency Gallery

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Agency Gallery

Agency Business briefs: June 2014

Agency Business briefs: June 2014

News on Publicis, Palio+Ignite, PulseCX, McCann HumanCare and GolinHarris

It's time to replace the FDA, says Newt Gingrich

It's time to replace the FDA, says Newt ...

Former Speaker of the House and presidential candidate Newt Gingrich has declared that it's time to replace FDA

Agency Business briefs: May 2014

Agency Business briefs: May 2014

Newson ID Media, Frontline Medical Communications and ContextMedia